About Fennec Pharmaceuticals
Fennec Pharmaceuticals (NASDAQ:FENC) focuses on developing and commercializing innovative cancer care therapies. With a specific interest in pediatric patients, Fennec aims to address unmet needs within this demographic, improving outcomes and quality of life. A notable project of theirs is PEDMARK™, a unique formulation designed to reduce the risk of hearing loss in children undergoing specific cancer treatments. The company is deeply committed to expanding its pipeline through rigorous research, strategic collaborations, and scientific advancements, all aimed at providing new, effective treatment options for cancer patients around the globe. Their objectives are centered on ensuring accessibility of their breakthrough therapies, enhancing patient care, and ultimately, achieving a significant impact in the oncology sector.
Snapshot
Operations
Products and/or services of Fennec Pharmaceuticals
- PEDMARK, a unique formulation of sodium thiosulfate designed for reducing cisplatin-induced hearing loss in pediatric cancer patients.
- Development of innovative cancer therapeutics aimed at improving survival and quality of life for patients.
- Research into treatments for rare cancers, focusing on areas with significant unmet medical needs.
- Collaborative projects with leading oncology research institutions to accelerate the development of effective cancer treatments.
- Investments in advanced drug delivery technologies to enhance the efficacy and safety of chemotherapy drugs.
- Advancement of a pipeline of early-stage oncology compounds targeting a variety of cancer types.
Fennec Pharmaceuticals executive team
- Mr. Jeffrey S. HackmanCEO & Director
- Mr. Robert C. AndradeChief Financial Officer
- Dr. Pierre S. Sayad M.S., Ph.D.Chief Medical Officer
- Mr. Terry EvansChief Commercial Officer
- Ms. Christiana Cioffi M.B.A.Chief Strategy Officer
- Mr. Mark GowlandController
- Mr. Lei FangPresident of Pharstat Inc